Abstract
Objective
To clarify the epidemiologic characteristics and risk of other tumors in survivors of gynecological tumors.
Materials and methods
This is a retrospective study based on the Surveillance, Epidemiology, and End Results database (SEER).
Results
The morbidity of other malignant tumors in patients with gynecological cancer was 8.07%. The most common subsequent tumors are breast, lung, colorectal, thyroid, and bladder cancers. Taking the incidence rate of the general population as reference, the second tumor with the highest relative risk in patients with cervical cancer is vulvar cancer. Bladder cancer is the second tumor with the highest relative risk value both in patients with corpus and ovarian cancer. The median period from the diagnosis of the initial tumor to the diagnosis of the second tumor was 5 years. Most patients with other tumors following gynecological cancer showed worse prognosis than patients with gynecological tumors only. However, thyroid cancer following ovarian cancer is a protective factor in survival.
Conclusion
Patients with gynecological tumors have a significantly higher risk of malignant tumors in other systems compared to ordinary population. It is necessary to be vigilant against subsequent high-risk tumors and tumors with poor prognosis within 5 years of initial diagnosis.
Similar content being viewed by others
Data availability
Data availability is not applicable to this article as no new data were created in this study. The data for analysis was from SEER database and may be downloaded at https://seer.cancer.gov/data/.
Change history
05 June 2024
A Correction to this paper has been published: https://doi.org/10.1007/s00404-024-07579-y
References
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin 68(6):394–424
Marth C, Landoni F, Mahner S, et al (2017) ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(4):72–83
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Emons G, Mustea A, Tempfer C (2020) Tamoxifen and endometrial cancer: a janus-headed drug. Cancers (Basel) 12(9):2535
Hu R, Hilakivi-Clarke L, Clarke R (2015) Molecular mechanisms of tamoxifen-associated endometrial cancer. Oncol Lett 9:1495–1501
Ignatov A, Ortmann O (2020) Endocrine risk factors of endometrial cancer: polycystic ovary syndrome, oral contraceptives, infertility, tamoxifen. Cancers (Basel) 12(7):1766
Guo J, Zhang Y, Qian H et al (2019) The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter? Arch Gynecol Obstet 300(5):1399–1404
National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/. [accessed October 8, 2020]
Siegel RL, Miller KD, Jemal A et al (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30
Bhat-Nakshatri P, Kumar B, Simpson E et al (2020) Breast cancer cell detection and characterization from breast milk-derived cells. Cancer Res 80(21):4828–4839
Oudkerk M, Liu S, Heuvelmans MA et al (2021) Lung cancer LDCT screening and mortality reduction – evidence, pitfalls and future perspectives. Nat Rev Clin Oncol 18(3):135–151
Nakamura Y, Taniguchi H, Ikeda M et al (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26(12):1859–1864
Henderson NC, Rieder F, Wynn TA (2020) Fibrosis: from mechanisms to medicines. Nature 587(7835):555–566
de Martel C, Plummer M, Vignat J, Franceschi S et al (2017) Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141(4):664–670
Faber MT, Sand FL, Albieri V et al (2017) Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer 141(6):1161–1169
Wei F, Li M, Wu X et al (2018) The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: a population-based study. Int J Cancer 142(6):1244–1251
Bertoli HK, Thomsen LT, Iftner T, Dehlendorff C, et al (2020) Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: a population-based prospective cohort study. Gynecol Oncol 157(2):456–462
Mitchell AJ, Chan M, Bhatti H et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174
Afrisham R, Paknejad M, Soliemanifar O et al (2019) The influence of psychological stress on the initiation and progression of diabetes and cancer. Int J Endocrinol Metab 17(1):e67400
Kruk J, Aboul-Enein BH, Bernstein J, et al (2019) Psychological stress and cellular aging in cancer: a meta-analysis. Oxid Med Cell Longev 1270397
Schlumberger M, Leboulleux S (2021) Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol 17(3):176–188
Rahman ST, McLeod DSA, Pandeya N et al (2019) Understanding pathways to the diagnosis of thyroid cancer: are there ways we can reduce over-diagnosis? Thyroid 29(3):341–348
Liu J, Xu T, Ma L et al (2021) Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer. Front Oncol 11:593479
Poppe K (2021) Management of endocrine disease: thyroid and female infertility: more questions than answers?! Eur J Endocrinol 184(4):123–135
Zhang C, Xia G, Tsang BK (2011) Interactions of thyroid hormone and FSH in the regulation of rat granulosa cell apoptosis. Front Biosci 3:1401–1413
Cardenas C, Alvero AB, Yun BS et al (2016) Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocr Relat Cancer 23(9):411–422
Gharwan H, Bunch KP, Annunziata CM (2015) The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr Relat Cancer 22:339–363
Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303–14
Acknowledgements
We thank SEER database for sharing the resource. The authors thank AiMi Academic Services (www.aimieditor.com) for English language editing and review services.
Funding
Not applicable.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors report no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Guo, J., Wang, H., Zou, X. et al. The challenge of survivors of gynecological carcinomas: a retrospective study on occurrence of second tumors. Arch Gynecol Obstet (2024). https://doi.org/10.1007/s00404-024-07497-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00404-024-07497-z